Get the Stockscreener App
9.12
3.32%
-0.28
Elicio Therapeutics Inc stock is traded at $9.12, with a volume of 6,430.
It is down -3.32% in the last 24 hours and up +50.71% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
See More
Previous Close:
$9.40
Open:
$9.0366
24h Volume:
6,430
Relative Volume:
0.18
Market Cap:
$113.30M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.3564
EPS:
-25.5891
Net Cash Flow:
$-66.04M
1W Performance:
-2.39%
1M Performance:
+50.71%
6M Performance:
+110.37%
1Y Performance:
+169.67%
1-Day Range:
$9.0366
$9.2547
1-Week Range:
$8.50
$9.50
52-Week Range:
$3.3419
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
9.0878 | 113.30M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.90 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.63 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.12 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.10 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Elicio Therapeutics Inc Stock (ELTX) Latest News
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - Insider Monkey
Elicio Therapeutics secures $10 million in direct offering - MSN
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Elicio Therapeutics stock slides on $10M securities offering - MSN
Elicio Therapeutics Advances with New Clinical Updates - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - The Manila Times
Elicio Therapeutics Secures FDA Support for ELI-002 Cancer Therapy Phase 3 Strategy - StockTitan
(ELTX) Investment Report - Stock Traders Daily
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Serina Therapeutics Appoints Former Jazz Pharmaceuticals Finance Executive Karen Wilson to Board - StockTitan
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Trading (ELTX) With Integrated Risk Controls - Stock Traders Daily
Elicio Therapeutics Advances ELI-002 and Secures Funding - Yahoo Finance
Elicio reports promising cancer vaccine trial results By Investing.com - Investing.com Canada
Elicio Therapeutics Presents Updated Results from ELI-002 - GlobeNewswire
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO - The Bakersfield Californian
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - Business Upturn
(ELTX) Investment Analysis and Advice - Stock Traders Daily
Elicio completes phase 2 enrollment for cancer vaccine By Investing.com - Investing.com Canada
Elicio completes phase 2 enrollment for cancer vaccine - Investing.com India
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - GlobeNewswire
Elicio Therapeutics Completes Phase 2 Trial Enrollment for Pancreatic Cancer Treatment - StockTitan
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio Therapeutics adjourns annual meeting due to lack of quorum - Investing.com
Elicio reports promising Phase 1 cancer vaccine trial results - Investing.com India
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting - GlobeNewswire
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study - The Bakersfield Californian
Elicio Therapeutics adjourns annual meeting due to lack of quorum By Investing.com - Investing.com UK
Jones Trading Initiates Coverage of Elicio Therapeutics (ELTX) with Buy Recommendation - MSN
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit - The Manila Times
Elicio Therapeutics to Present Clinical Data at the Society - GlobeNewswire
All You Need to Know About Elicio Therapeutics (ELTX) Rating Upgrade to Strong Buy - Yahoo Finance
Elicio Therapeutics announces new CFO and accounting officer By Investing.com - Investing.com Australia
Elicio Therapeutics announces new CFO and accounting officer - Investing.com
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):